Regulation of the pentose phosphate pathway by an androgen receptor–mTOR-mediated mechanism and its role in prostate cancer cell growth

被引:0
|
作者
E Tsouko
A S Khan
M A White
J J Han
Y Shi
F A Merchant
M A Sharpe
L Xin
D E Frigo
机构
[1] Center for Nuclear Receptors and Cell Signaling,Department of Biology and Biochemistry
[2] University of Houston,Department of Engineering Technology
[3] Houston,Department of Neurosurgery
[4] TX,Department of Molecular and Cellular Biology
[5] USA,Department of Pathology and Immunology
[6] University of Houston,undefined
[7] Houston Methodist Research Institute,undefined
[8] Baylor College of Medicine,undefined
[9] Baylor College of Medicine,undefined
[10] Dan L. Duncan Cancer Center,undefined
[11] Center for Genomic Medicine,undefined
[12] Houston Methodist Research Institute,undefined
来源
Oncogenesis | 2014年 / 3卷
关键词
prostate cancer; G6PD; pentose phosphate pathway; androgen receptor; mTOR; PTEN;
D O I
暂无
中图分类号
学科分类号
摘要
Cancer cells display an increased demand for glucose. Therefore, identifying the specific aspects of glucose metabolism that are involved in the pathogenesis of cancer may uncover novel therapeutic nodes. Recently, there has been a renewed interest in the role of the pentose phosphate pathway in cancer. This metabolic pathway is advantageous for rapidly growing cells because it provides nucleotide precursors and helps regenerate the reducing agent NADPH, which can contribute to reactive oxygen species (ROS) scavenging. Correspondingly, clinical data suggest glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway, is upregulated in prostate cancer. We hypothesized that androgen receptor (AR) signaling, which plays an essential role in the disease, mediated prostate cancer cell growth in part by increasing flux through the pentose phosphate pathway. Here, we determined that G6PD, NADPH and ribose synthesis were all increased by AR signaling. Further, this process was necessary to modulate ROS levels. Pharmacological or molecular inhibition of G6PD abolished these effects and blocked androgen-mediated cell growth. Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD. Accordingly, in two separate mouse models of Pten deletion/elevated mTOR signaling, Pb-Cre;Ptenf/f and K8-CreERT2;Ptenf/f, G6PD levels correlated with prostate cancer progression in vivo. Importantly, G6PD levels remained high during progression to castration-resistant prostate cancer. Taken together, our data suggest that AR signaling can promote prostate cancer through the upregulation of G6PD and therefore, the flux of sugars through the pentose phosphate pathway. Hence, these findings support a vital role for other metabolic pathways (that is, not glycolysis) in prostate cancer cell growth and maintenance.
引用
收藏
页码:e103 / e103
相关论文
共 50 条
  • [31] Regulation of MST1 and MST2 by mTOR and androgen receptor signaling in prostate cancer
    Collak, Filiz Kisaayak
    Luthringer, Daniel
    Kim, Hyung L.
    Chung, Leland
    Cinar, Bekir
    CANCER RESEARCH, 2011, 71
  • [32] Androgen Receptor regulation of HGF/Met pathway in clear cell renal cancer
    De Silva, D.
    Roy, A.
    Lee, M.
    Costello, R.
    Bottaro, D.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E35 - E36
  • [33] Androgen receptor remains essential for prostate cancer cell line growth in androgen depleted condition
    Dizeyi, N.
    Zhang, T.
    Wang, H.
    Balk, S. P.
    Yan, X.
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 807 - 807
  • [34] Regulation of androgen receptor expression by Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer
    Liu, Po-Yen
    Lin, Shinn-Zong
    Sheu, Jim Jinn-Chyuan
    Lin, Cheng-Tung
    Lin, Po-Cheng
    Chou, Yi-Wen
    Huang, Mao-Hsuan
    Chiou, Tzyy-Wen
    Harn, Horng-Jyh
    PROSTATE, 2013, 73 (05): : 531 - 541
  • [35] Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth
    Carey, JL
    Sasur, LM
    Kawakubo, H
    Gupta, V
    Christian, B
    Bailey, PM
    Maheswaran, S
    MOLECULAR ENDOCRINOLOGY, 2004, 18 (03) : 696 - 707
  • [36] Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells
    Hååg, P
    Bektic, J
    Bartsch, G
    Mocker, H
    Eder, IE
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 96 (3-4): : 251 - 258
  • [37] The impact of dual inhibition on the androgen receptor and mTOR pathway cross talk in vitro and in vivo in prostate cancer models
    Schayowitz, Adam
    Sabnis, Gauri
    Njar, Vincent
    Goloubeva, Olga
    Brodie, Angela
    CANCER RESEARCH, 2008, 68 (09)
  • [38] Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
    Kato, Minoru
    Banuelos, Carmen A.
    Imamura, Yusuke
    Leung, Jacky K.
    Caley, Daniel P.
    Wang, Jun
    Mawji, Nasrin R.
    Sadar, Marianne D.
    CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2744 - 2754
  • [39] Regulation of Androgen Receptor and Prostate Cancer Growth by Cyclin-dependent Kinase 5
    Hsu, Fu-Ning
    Chen, Mei-Chih
    Chiang, Ming-Ching
    Lin, Eugene
    Lee, Yueh-Tsung
    Huang, Pao-Hsuan
    Lee, Guan-Shun
    Lin, Ho
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (38) : 33141 - 33149
  • [40] Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth
    Moehren, Udo
    Papaioannou, Maria
    Reeb, Christina A.
    Hong, Wei
    Baniahmad, Aria
    MOLECULAR ENDOCRINOLOGY, 2007, 21 (05) : 1039 - 1048